Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1152W HIGH $4.18
Volume
106.95 K
Value Traded
16.77 K
Short % Float
16.89%
Days to Cover
1.0
+1.14%Week
-44.23%1 Month
-77.26%3 Month
-86.1%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
385.23 K
EPS (TTM)
-4.62
P/E Ratio
-
Ent. Value
-3.79 M
Total Shares
2.41 M
Float Shares
2.03 M
Insiders
15.87%
Institutions
18.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
RKDA Catalyst Timeline
Dated clinical, regulatory and corporate events for Arcadia Biosciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How RKDA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RKDA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kawakami MarkOfficer (Chief Financial Officer) | Buy | 700 2,681 held | $2.49 | 02/03/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in RKDA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RKDA for Q2 2026. | ||||
Ownership Trends
RKDA Short Interest
Shares sold short, counted twice a month.
16.89%
Short % of Float
of tradable shares sold short
342.8K
Shares Sold Short
+286.3% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
5.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RKDA ranks across every disease it competes in
Competitive Position is a premium feature
See how RKDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRKDA News
-RKDA
Aug 13, 2026▲ +9.6%on this news· ran to -22% by day 3
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
Arcadia Biosciences reported its financial results for Q2 and the first half of 2026, highlighting a net cash usage of only $319K and a cash balance of $4.2 million. Despite flat sales due to inventory issues, July sales for Zola exceeded $740K, indicating potential growth. The company also raised $4 million through a private placement to support product launches.
Read more →-RKDA
Jun 13, 2026▼ -10.8%on this news· ran to -25% by day 3
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences, Inc. has successfully closed a $4 million private placement under Nasdaq rules. The offering involved the sale of nearly 3.9 million shares of common stock and preferred investment options. The funds will be used for working capital and corporate purposes, although the securities are unregistered and subject to stockholder approval.
Read more →-RKDA
Jun 12, 2026Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Arcadia Biosciences (RKDA) has announced a private placement of approximately $4 million, involving the sale of nearly 3.9 million shares of common stock and associated preferred investment options. The offering is priced at $1.03 per share and is expected to close on June 12, 2026, pending customary conditions. The funds will be used for working capital and general corporate purposes.
Read more →-RKDA
May 14, 2026Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) reported its first-quarter 2026 financial results, highlighting an 18% increase in Zola coconut water volumes year-over-year. However, total revenues dropped by 8%, resulting in a significant net loss of $4.4 million compared to a gain in the same period last year. The company's selling, general, and administrative expenses reached a historic low, and future product launches are anticipated. Despite these positive aspects, the company indicated a need for additional funding to support ongoing operations.
Read more →-RKDA
Mar 27, 2026Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
Arcadia Biosciences, Inc. reported its financial results for Q4 and full year 2025, highlighting a 17% increase in Zola revenues. However, total revenues decreased by 4% year-over-year, influenced by the absence of GLA oil sales. The company also announced the termination of its proposed business combination with Roosevelt Resources, while reducing SG&A expenses significantly.
Read more →-RKDA
Jan 12, 2026▼ -11.6%on this news
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds
Arcadia Biosciences (RKDA) has announced the exercise of preferred investment options, generating approximately $2.1 million in gross proceeds. The options allow investment in 808,595 shares at a reduced price, reflecting a strategic financial move. Furthermore, the company plans to issue new preferred investment options for additional funding. Proceeds from the exercise will be used for working capital and general corporate purposes. The closing of this offering is anticipated to occur on or about January 12, 2026, pending customary conditions.
Read more →-RKDA
Dec 26, 2025▼ -14.5%on this news· ran to -35% by day 3shared move
Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources
Arcadia Biosciences announced the termination of its proposed business combination with Roosevelt Resources. CEO T.J. Schaefer stated that the company will explore strategic alternatives to enhance shareholder value. Despite this setback, Arcadia has streamlined operations and continues to grow its Zola brand, while holding shares in Above Food Ingredients Inc.
Read more →-RKDA
Nov 7, 2025▼ -5.4%on this news
Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) reported its financial results for Q3 2025, highlighting a year-to-date revenue increase of 26% for Zola coconut water. Despite an overall revenue decrease in Q3 due to absent sales of GLA oil, the company noted significant improvements in gross profit margins and cash management. The company is also navigating the complexities of a pending business combination with Roosevelt Resources amidst a federal government shutdown. Net income attributable to common stockholders showed notable improvement compared to the previous year.
Read more →-RKDA
Aug 14, 2025Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) reported an 11% year-over-year increase in revenues for the second quarter of 2025, driven primarily by a 24% growth in Zola coconut water sales. The company also eliminated $1 million in liabilities, contributing to an improved financial outlook. However, a significant net loss of $4.5 million was reported, largely due to a credit loss related to a note receivable from Above Food. The ongoing business combination with Roosevelt Resources is proceeding, emphasizing the company’s commitment to strategic transitions.
Read more →-RKDA
May 8, 2025Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) reported a strong performance in the first quarter of 2025, with revenues rising 22% driven primarily by significant growth in Zola coconut water sales. The company also achieved a notable net income of $2.6 million, highlighting an impressive turnaround from a loss in the previous year. Additionally, Arcadia made strategic moves by selling patents for $750,000 and eliminating $1 million in liabilities, all while preparing for a business combination with Roosevelt Resources. The management expressed confidence in maintaining growth momentum as they progress with operational streamlining.
Read more →-RKDA
Mar 20, 2025Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights
Arcadia Biosciences (RKDA) reported a strong financial performance with a 56% revenue increase in Q4 2024 and 13% for the full year, driven by significant growth in its Zola coconut water brand. The company also announced a business combination with Roosevelt Resources, which aims to bolster its market presence. Despite this progress, Arcadia faced a rising net loss attributable to common stockholders in Q4, attributed mainly to changes in stock liabilities. However, cost controls were highlighted as a positive aspect, leading to the lowest operational cash use since going public.
Read more →-RKDA
Dec 11, 2024Arcadia Biosciences & Roosevelt Resources Business Combination December 2024 Filed by Arcadia Biosciences, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Sec
Arcadia Biosciences has filed for a business combination with Roosevelt Resources slated for December 2024. The filing is made under the relevant securities laws, and outlines potential benefits including enhanced operational capabilities and future growth opportunities for the combined entity. However, there are risks involved, such as the need for stockholder approval and uncertainties regarding post-transaction integration. The forward-looking statements included in the filing highlight various risks that could lead to different outcomes than expected.
Read more →-RKDA
Dec 6, 2024ARCADIA BIOSCIENCES (RKDA) ENTERS INTO BUSINESS COMBINATION AGREEMENT WITH ROOSEVELT RESOURCES IN ALL-STOCK TRANSACTION
Arcadia Biosciences (RKDA) has entered into a definitive securities exchange agreement with Roosevelt Resources, marking a significant all-stock transaction. The agreement, which expects to close in the first quarter of 2025, will result in Arcadia issuing shares to Roosevelt’s partners. This move comes after Arcadia's strategic review aimed at maximizing shareholder value and streamlining operations. Roosevelt Resources brings a large carbon capture and oil project with considerable development potential, positioning the combined entity for future growth.
Read more →-RKDA
Nov 12, 2024Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2024 Financial Results and Business Highlights -- Total revenues increased 18% compared to Q3 2023 – -- Zola coconut water revenues grew 55% year over year
Arcadia Biosciences (RKDA) reported strong financial results for Q3 2024, with total revenues rising 18% year over year, largely driven by the success of its Zola coconut water product, which experienced a 55% revenue growth. Retail distribution for Zola has also increased significantly, up 68% compared to last year. The company is experiencing an overall positive trend in revenue and market share, despite facing increased operating expenses and continued net losses. Arcadia's management expressed optimism regarding their strategic achievements and long-term business transformation.
Read more →-RKDA
Aug 13, 2024Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2024 Financial Results and Business Highlights -- Company closes $4M transaction with Corteva Agriscience -- -- Above Food Corp acquires GoodWheat TM bra
Arcadia Biosciences (RKDA) reported its financial results for the second quarter and first half of 2024, highlighting significant operational improvements. The company secured $4 million through the sale of its resistant starch wheat trait to Corteva Agriscience and sold its GoodWheat brand to Above Food Corp for a similar amount over three years. Zola coconut water saw a remarkable 42% increase in sales year-over-year, indicating strong market demand. However, overall revenue for the first half decreased modestly, and the company is still adjusting its organizational structure.
Read more →-RKDA
May 14, 2024▲ +31.5%on this news· ran to +50% by day 3
ARCADIA BIOSCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION On
Arcadia Biosciences, Inc. has completed the sale of its GoodWheat business to Above Food Corp. for a total consideration of $4,000,000, which includes a cash payment and a promissory note. The company has released unaudited pro forma consolidated financial statements reflecting this transaction. While this sale provides immediate cash flow, it raises concerns about the company's ongoing financial performance and future operational focus. The pro forma information is illustrative and may not indicate the company’s future conditions accurately.
Read more →-RKDA
May 9, 2024Arcadia Biosciences (RKDA) Announces First Quarter 2024 Financial Results and Business Highlights – Revenues increase sequentially and year-over-year – – Loss from continuing operations is at lowest
Arcadia Biosciences (RKDA) reported its first quarter 2024 results, showing a slight increase in revenues compared to the previous year, attributed to its GoodWheat and Zola product lines. The loss from continuing operations has decreased to the lowest level in six years, while operating expenses have seen a notable decline. The company continues to focus on expanding the distribution of its products, with GoodWheat and Zola set to be key growth drivers. Improvements were also noted in net loss attributable to common stockholders, significantly enhanced from the prior year's quarter.
Read more →-RKDA
Mar 28, 2024Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights -- Second continuous year of gross profit growth -- -- Total SG&A expenses declined to the lowest levels si
Arcadia Biosciences (RKDA) reported its fourth-quarter and full-year financial results for 2023, highlighting a second consecutive year of gross profit growth. The company's focus on its GoodWheat product line has led to increased revenues and the introduction of new product categories, including pancake mixes and mac & cheese. Despite a reduction in SG&A expenses and operational improvements, the overall revenues for the year decreased compared to 2022. The company also experienced significant net losses, though these improved marginally from the previous year.
Read more →-RKDA
Nov 9, 2023Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2023 Financial Results and Business Highlights -- Increased revenue from continuing operations 20% quarter over quarter -- -- Lowest SG&A expenses since 2019 -- -
Arcadia Biosciences (RKDA) reported strong third quarter financial results with a 20% increase in revenue from continuing operations compared to the previous quarter. The company's SG&A expenses reached their lowest level since 2019, contributing to a more streamlined cost structure. The introduction of GoodWheat Mac & Cheese is set to expand their product categories, capitalizing on the growing demand for healthier options. However, year-over-year revenue remains down by 38%, and the company continues to face significant net losses.
Read more →-RKDA
Aug 10, 2023Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2023 Financial Results and Business Highlights • GoodWheat TM expands into breakfast category with the launch of better-for-you pancake and waffle
Arcadia Biosciences (RKDA) recently announced its second-quarter and first-half 2023 financial results, highlighting a decrease in total revenues, which fell by $2.5 million and $4.2 million respectively. The company's latest initiatives, including the launch of GoodWheat pancake and waffle mixes, aim to capitalize on growth in the food sector while reducing operating costs by winding down its Body Care brands. Despite the decrease in revenues, Arcadia has reported an improvement in net income for the second quarter, partially due to significant strategic shifts and a newly engaged review process for exploring potential transactions. The financial performance and strategic direction reflect a focus on maximizing shareholder value amidst operational challenges.
Read more →About Arcadia Biosciences, Inc.
Headquarters5956 SHERRY LANE, DALLAS, TX
BIOPHARMAWATCH ELITE PLUS
Trade the next RKDA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime